Using prognosis to guide early detection and treatment selection in non-metastatic prostate cancer.
View / Open Files
Publication Date
2019-04Journal Title
BJU international
ISSN
1464-4096
Volume
123
Issue
4
Pages
562-563
Language
eng
Type
Article
This Version
AM
Physical Medium
Print-Electronic
Metadata
Show full item recordCitation
Gnanapragasam, V., Barrett, T., Massie, C., Pacey, S., & Warren, A. (2019). Using prognosis to guide early detection and treatment selection in non-metastatic prostate cancer.. BJU international, 123 (4), 562-563. https://doi.org/10.1111/bju.14637
Abstract
Over recent years there has been an increasing awareness that our ideas on the lethality of primary non‐metastatic prostate cancer may need to change. This concept has emerged from a number of different sources including randomised controlled trials, reports from mature active surveillance programmes, and prognostic modelling work in large populations 1, 2. The evidence suggests that for many men without metastatic disease (85% of all presentations from the recent UK National Prostate Cancer Audit) tumours will evolve slowly and will not translate into cancer‐related mortality, at least, not within the first 10–15 years of its natural history.
Sponsorship
Cancer Research UK (26718)
Identifiers
External DOI: https://doi.org/10.1111/bju.14637
This record's URL: https://www.repository.cam.ac.uk/handle/1810/290966
Rights
Licence:
http://www.rioxx.net/licenses/all-rights-reserved